Eli Lilly and Company has launched the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. This investment—part of the company’s strategy to advance RNA based therapeutics—builds on the 2020 acquisition and expansion of Prevail Therapeutics, a gene therapy pioneer based in New York City. Working together, researchers in both Boston and New York will leverage promising RNA and DNA-...